Data / Drug companies / Horizon Therapeutics USA, Inc.
Horizon Therapeutics USA, Inc.: 12 products in the FDA NDC directory, labeler code 75987
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Horizon Therapeutics USA, Inc. (labeler code 75987) lists 12 products in the FDA National Drug Code Directory, covering 7 finished drugs by generic name. By type: 12 prescription drugs. Its main marketing category is new drug applications (NDA). The newest product started marketing on August 29, 2025.
The request: Watch Horizon Therapeutics USA, Inc. (FDA labeler code 75987): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 75987
- Products in commercial distribution
- 12
- Packages
- 15
- Finished drugs by generic name
- 7
- Prescription products
- 12
- Over the counter products
- 0
- Flagged as original packager
- 10 of 10 products that carry the flag
- Started marketing in the last 12 months
- 0
- Earliest marketing start
- April 30, 1996
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| New drug applications (NDA) | 7 | 58.3% |
| Biologics (BLA) | 5 | 41.7% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 12 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Cysteamine bitartrate | 4 | 2 |
| Pegloticase | 2 | 1 |
| Sodium phenylbutyrate | 2 | 7 |
| Interferon gamma-1b | 1 | 2 |
| Glycerol phenylbutyrate | 1 | 8 |
| Teprotumumab | 1 | 1 |
| Inebilizumab | 1 | 1 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, solution | 3 | 25% |
| Capsule, delayed release pellets | 2 | 16.7% |
| Granule, delayed release | 2 | 16.7% |
| Liquid | 1 | 8.3% |
| Tablet | 1 | 8.3% |
| Powder | 1 | 8.3% |
| Injection, powder, lyophilized, for solution | 1 | 8.3% |
| Injection | 1 | 8.3% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
| Class | Products |
|---|---|
| Cystine Depleting Agent | 4 |
| Nitrogen Binding Agent | 3 |
| Uric Acid-specific Enzyme | 2 |
| Interferon gamma | 1 |
| Insulin-like Growth Factor-1 Receptor Inhibitor | 1 |
| CD19-directed Cytolytic Antibody | 1 |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Krystexxa | 75987-058 | Injection, solution | Biologics (BLA) | August 29, 2025 |
| Uplizna | 75987-150 | Injection | Biologics (BLA) | June 11, 2020 |
| Procysbi | 75987-145 | Granule, delayed release | New drug applications (NDA) | February 14, 2020 |
| Procysbi | 75987-140 | Granule, delayed release | New drug applications (NDA) | February 14, 2020 |
| Tepezza | 75987-130 | Injection, powder, lyophilized, for solution | Biologics (BLA) | January 21, 2020 |
| Actimmune | 75987-111 | Injection, solution | Biologics (BLA) | December 1, 2013 |
| Procysbi | 75987-101 | Capsule, delayed release pellets | New drug applications (NDA) | April 30, 2013 |
| Procysbi | 75987-100 | Capsule, delayed release pellets | New drug applications (NDA) | April 30, 2013 |
| Ravicti | 75987-050 | Liquid | New drug applications (NDA) | February 28, 2013 |
| Krystexxa | 75987-080 | Injection, solution | Biologics (BLA) | September 14, 2010 |
| Buphenyl | 75987-060 | Tablet | New drug applications (NDA) | May 13, 1996 |
| Buphenyl | 75987-070 | Powder | New drug applications (NDA) | April 30, 1996 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.